Clinical Trial Search

Primary: The Number of Participants With Treatment Emergent Adverse Events (All TEAEs). — 5; 5; 0 Participants

Primary: The Number of Participants With Treatment Emergent Adverse Events Cumulative to Week 48 by Maximum Severity — 27; 55; 29; 58 Participants

Primary: Comparison of Mean Average (Standard Deviation) Total Palmar Gravimetric Sweat Production (GMSP) Between Subject Groups (Adult Patients With Hyperhidrosis Versus Healthy…

Primary: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity…

Primary: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity…

Primary: Mean Change From Baseline to Week 2 in Hand Sweating Severity Score — -2.14; -0.56; -1.64; -3.03 score on a scale — p=0.244

Primary: Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of Axillary Sweating Daily Diary (ASDD) Item #2 From Baseline at Week 4 — 66.1; 26.9…

Primary: Change From Baseline in Palmar Sweat Production — 44.8; 43.2; 37.8; 24.9 mg/min

Primary: Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of ASDD Item #2 From Baseline at Week 4 — 52.8; 28.3 percent of subjects — p=<0.001

Primary: Number of Participants With Hyperhidrosis Disease Severity Scale (HDSS) Score Reduction at Day 30 Post Second Treatment — 11 participants

Primary: Safety of the N-SWEAT Patch — 14; 4 Participants

Primary: Percentage of Responders Assessed by Gravimetric Measurement at Week 4 in the First Treatment Phase — 96.2; 45.9 percentage of participants — p=<0.001

Primary: Long-term Safety Assessed Through Adverse Events and Local Skin Reactions — 148; 153; 28; 120 Adverse Events and Local Skin Reactions

Primary: Number of Patients With Improvement in Hyperhidrosis Severity at Week 1 or Week 4 as Measured by the Hyperhidrosis Disease Severity Scale (HDSS). — 4 participants

Primary: Percentage of Participants With Both a Change From Baseline in Hyperhidrosis Disease Severity Scale (HDSS) Score by ≥ 2 Points and a Change From Baseline in Gravimetric…

Primary: Percentage of Subjects That Report an HDSS Score of 1 or 2 at 30 Days. — 54; 89 Percentage of Participants — p=<0.001

Primary: Change in Sweating Assessed Using Gravimetry — 267.91; 57.36; 155.14 mg

Primary: Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 — 14; 20; 21; 18 Participants

Primary: Percentage Change of Sweat Rate (mg/Min) at Baseline Compared to 3 Months — 73.8; 58.8 Percentage Change — p=>0.01

Primary: Mean Plasma Concentration After Repeat Dosing of Umeclidinium — 33.09; 29.86; 41.22; 42.72 picogram per millilitre (pg/ml)

Primary: Posterior Probability That the Response Rate is Greater Than 50% — 1; 0.9997 Posterior Probability

Primary: ASDD-m Sweat Severity Score — 1.2; 3.6 score on a scale of 0-10

Primary: Percentage of Photographs Identified Accurately — 84.8 % of photographs identified correctly

Primary: Change in Sweating Assessed Using Gravimetry — -104.50; -90.85 mg

Primary: Number of Treatment Emergent Adverse Events by Severity — 14; 4; 3; 0 Number of Events by Severity

Primary: Proportion of Subjects Achieving at Least 2-point Decrease in Hyperhidrosis Disease Severity Scale (HDSS) From Baseline to Week 4 — 35; 37; 29; 36 Participants

Primary: Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 — 10; 10; 9; 10 Participants

Primary: Change of Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) Score From Baseline to End of Therapy — -1.30; -2.02; -2.09; -2.10 score on a scale

Primary: Adherence — 1; 8; 3 millimeters — p=.037

Primary: Ease of Use Day 21 vs Day 0 — 6.47; 0.6 score on a scale